Get started

Stockstotrade

$CAN Announced all time high purchased bitcoin mining machinesCanaan Announces Improved Revenue Visibility in 2021 today announced that its revenue visibility has improved substantially in 2021 as a result of attaining purchase orders totaling more than 100,000 units of bitcoin mining machines from customers in North America. Many of those purchase orders were placed with prepayment and will likely occupy the Company’s current manufacturing capacity entirely for the full year of 2021 and beyond. With those fully committed purchase orders, the Company now enjoys a much higher degree of revenue visibility and more precise forecast. As such, the Company is able to leverage such information and additional liquidity to conduct its component purchases, production scheduling, warehousing and logistics. In late 2020, we shifted our client base to mostly publicly traded companies and bitcoin-focused investment funds which tend to place sizable orders with longer-term commitment. As a result, we can now forecast our revenue much more precisely. This development from Canaan isn't a total surprise. After all, the price of Bitcoin has risen dramatically in recent months, and that attracts more miners to the pool. When more miners join the Bitcoin blockchain network, it adds to the hashrate. According to Blockchain.com, the total hashrate for Bitcoin has spiked to all-time highs in recent days. finance.yahoo.com www.fool.com
NASDAQ:CAN
by AlenCiken
$LKCO Announces $15.0 Million Registered Direct OfferingLuokung Technology Corp. Announces $15.0 Million Registered Direct Offering today announced that it has entered into a securities purchase agreement with certain institutional investors for a registered direct offering of approximately $15.0 million of ordinary shares at a price of $0.888 per share. The Company will issue a total of 16,891,892 ordinary shares to the institutional investors. As part of the transaction, the Company will also issue to the investors warrants ("Warrants") for the purchase of up to 8,445,946 ordinary shares at an exercise price of $1.11 per share, which Warrants will have a term of three years from the date of issuance.
NASDAQ:LKCO
by AlenCiken
2
Expedia CEO: We’re seeing plenty of signs of demandWe’re seeing plenty of signs of demand:’ Expedia CEO on travel demand amid pandemic. As we said yesterday on our earnings, we are seeing some signs of improvement in the first month of the year. It started around the holidays. And we've been slowly modestly improving from there. January was better than December. It's kind of a story of waiting. And there are some countries like the US that are stronger, where people are moving around more. There are areas in Asia as well. And then there are places like Europe, where things are still fairly locked down. So it's really where people are feeling more confident about travel, where people are allowed to travel. We're certainly seeing plenty of signs of demand. It's just a question of consumer confidence and risk tolerance and what governments are allowing people to do. finance.yahoo.com
NASDAQ:TRVG
by AlenCiken
$TRCH Announces Closing of Underwritten Public OfferingTorchlight Prices Underwritten Public Offering of Common Stock today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $1.20 per share. The Company has also granted to the underwriter a 30-day option to acquire an additional 3,000,000 shares to cover overallotments in connection with the offering. Gross proceeds of the offering will be $24 million before the underwriting discount and offering expenses payable by the Company, assuming no exercise of the overallotment option. The offering is expected to close on February 10, 2021, subject to customary closing conditions. finance.yahoo.com Torchlight Announces Closing of Underwritten Public Offering of Common Stock for Gross Proceeds of $27.6 Million today announced the closing of an underwritten public offering of 23,000,000 shares of its common stock at a price of $1.20 per share, which included the full exercise of the underwriter's over-allotment option, for gross proceeds to Torchlight of $27.6 million before deducting the underwriting discount and offering expenses payable by Torchlight. finance.yahoo.com
T
by AlenCiken
2
Thermal Kinetic is Awarded Al-Corn Clean Fuels Sanitizer ProjectThermal Kinetics is Awarded Al-Corn Clean Fuels Sanitizer-Grade Ethanol Project $RCMT today provided an update on its recently obtained projects to assist its clients in producing higher grades of ethanol for use in beverage and hygienic applications such as sanitizer-grade ethanol. The recent projects include both USP Grade (US Pharmacopeia) and GNS Grade (Grain Neutral Spirits). As industry scrambles to retool and pivot to assist in the fight against Covid-19, demand for sanitizers has surged dramatically, and the area is expected to see continued growth. Thermal Kinetics, a division of RCM Technologies (USA), Inc., has been contracted by Al-Corn Clean Fuels to expand its existing Fuel Ethanol facility to produce 20,000,000 gallons per year of USP Grade Ethanol to meet the growing need for the sanitizer market. Thermal Kinetics is executing additional projects related to the growing demand for sanitizer-grade ethanol. Thermal Kinetics has been contracted by several other customers during the second and third quarters of 2020 to provide detailed design engineering to expand the production of sanitizer-grade ethanol to their existing client bases in the North American market. The demand for higher grade ethanol has outgrown product availability due to the current Covid-19 pandemic finance.yahoo.com
NASDAQ:RCMT
by AlenCiken
3
$OLB Announces Plan to Offer Cryptocurrency Payment OptionsOLB Group Announces Plan to Offer Cryptocurrency Payment Options via Blockchain Technology on its OMNICOMMERCE Platform and SecurePay TM Gateway OLB’s SecurePay TM Payment Gateway to Enable Merchants to Seamlessly Offer Cryptocurrency Payments $OLB upgraded its SecurePay payment gateway system to support Cryptocurrencies including Bitcoin, Ethereum, USDC and DAI across all merchant platforms. SercurePay is compatible with mobile, tablet-based and cloud infrastructure and will be integrated into the merchants current payment ecosystem, in order to enable the acceptance of Cryptocurrency payments. finance.yahoo.com
NASDAQ:OLB
by AlenCiken
$AUVI Announces Acquisition of the Airocide Technology PlatformApplied UV Announces Acquisition of the Airocide(R) Technology Platform for Airborne Pathogen Reduction Developed with NASA as a patented pathogen killing technology Proprietary photocatalytic oxidation process thoroughly destroys viruses, bacteria, spores, and fungi as well as other carbon-based molecules Airocide® air disinfection technology compliments and expands the SteriLumen platform, together providing a more comprehensive solution for air and surface Accelerates the strategy to grow revenues through complimentary acquisitions Enhances scale in the fast-growing disinfection device market Akida's revenue for the full calendar year 2020 is estimated to be $4.7 million with EBITDA of approximately $921,000. Airocide technology is widely accepted and currently used by nationally recognized brands such as Hard Rock Café, the US Army, Stag's Leap vineyards and many more. finance.yahoo.com
A
by AlenCiken
Closing of an Upsized $20.7 Million Underwritten Public OfferingInspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering $NSPR today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering expenses payable by InspireMD. The offering is comprised of 29,032,258 Units, priced at a public offering price of $0.62 per Unit, with each Unit consisting of one share of Common Stock and one Series G Warrant to purchase one-half of one share of Common Stock, at an exercise price of $0.682 per share and expiring on the fifth anniversary of the date of issuance. finance.yahoo.com InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option $NSPR today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by InspireMD. finance.yahoo.com
N
by AlenCiken
$JG Partners with Kuaishou to Improve Monetization EfficiencyAurora Mobile $JG Partners with Kuaishou to Improve Monetization Efficiency $JG today announced that it has entered into a partnership agreement with Kuaishou Technology (01024.HK) (“Kuaishou”), China’s leading short video content community and social platform, to improve advertising monetization efficiency. By leveraging its powerful artificial intelligence (“AI”) and advanced analysis technologies, Aurora Mobile's advertisement SaaS services will enable Kuaishou to help brands and performance-based advertisers to accurately target potential customers, enhance advertising conversion rate, reduce operational costs, and promote a mutually beneficial relationship between Kuaishou and advertisers on its platform. The short-form video market continues to experience huge growth. Short-form video advertising that features high traffic and conversion rates has become a preferred marketing approach for many brands and performance-based advertisers. According to the cooperation agreement, Aurora Mobile will benefit from a revenue share agreement based on advertising revenues allocated to Kuaishou if the labels provided by Aurora Mobile are used by advertisers on the platform. finance.yahoo.com
NASDAQ:JG
by AlenCiken
$ZOM could surge 100% due to upcoming launch of TruformaTangible catalyst behind surge is due to the upcoming launch of Truforma , Zomedica’s point-of-care (POC) diagnostic device for the detection of thyroid disease in dogs and cats and adrenal disease in dogs. The platform will hit the market on March 30 , and ahead of the product’s debut, the company has also just nabbed a vital distribution deal. Last week, Zomedica announced an agreement with Miller Veterinary Supply who will distribute Truforma. Miller is the U.S.’s oldest wholesale veterinary distributor and one of the veterinary industry’s fastest growing businesses. The company will be Zomedica’s representative in the eastern and mid-eastern states. Its sales and customer service efforts will be bolstered by sales representatives assigned by Zomedica, which the company is currently recruiting as it prepares for the launch. The pet market has been a prime beneficiary of the pandemic’s stay-at-home mandates and according to the American Pet Products Association, spending in the segment reached a record $99 billion in the U.S. last year. Outlay on diagnostic care in this market is expected to grow to $2.8 billion in 2024 from $1.7 billion in 2019. H.C. Wainwright analyst Swayampakula Ramakanth says that ahead of Truforma’s debut, the agreement “strengthens the commercial machinery.” “We are encouraged by the progress in commercial preparation for the upcoming launch, and accordingly we are raising the probability of launch to 90%, up from 75% previously,” the 5-star analyst said. “Additionally, due to the lower yield of the long-term Treasury note that has resulted in a lower risk-free rate and a lower market risk premium, we have adjusted the discount rate to 6% from 12%.” To this end, Ramakanth boosted his price target on ZOM from $0.3 to $1.2, suggesting upside of an additional 20% from current levels. Needless to say, Ramakanth’s rating stays a Buy. finance.yahoo.com
AMEX:ZOM
by AlenCiken
$AREC Announces Filing of SPAC Registration Statement$AREC American Resources Corporation Announces Filing of SPAC Registration Statement $AREC Company's SPAC is targeting acquisitions in the land holding and resource industry, and will focus on advancing land and resource assets towards a modern-day business model of clean energy, recycling and redevelopment, and social impact. $AREC today announced that American Acquisition Opportunity Inc., a special purpose acquisition company (the "SPAC" or "AAOI"), in which the Company has an indirect investment, filed a Registration Statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission ("SEC") on February 4, 2021 in connection with a proposed initial public offering of its units. The proposed public offering is expected to have a base offering size of $100 million, or up to $115 million if the underwriters' over-allotment option is exercised in full. finance.yahoo.com
NASDAQ:AREC
by AlenCiken
3
Sabra Capital Partners places a $7 target on SupercomSeeking alpha: Sabra Capital Partners places a $7 target on Supercom. Explosive Potential, Limited Downside: We view the base level value of the Company to be $7.00 per share based on a multi-year estimate that revenues will rebound back to $35mm. High conviction. While none of its coronavirus tracking pilots have materialized into a formal, large scale contract, news is gaining momentum in the Company’s backyard, Israel. seekingalpha.com
NASDAQ:SPCB
by AlenCiken
2
Why ATA Creativity Skyrocketed 951% yesterdayWhy ATA Creativity Skyrocketed 951% yesterday There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. ATA shares were buoyed — thanks to discussions stock trading groups on Facebook, Discord chat rooms, the r/Daytrading subreddit, Twitter hashtags, and YouTube channels before the market opened. Many of these posts mentioned the advantages of the high volume and relatively low float (31.74M) of the stock. ATA Creativity is not on the list of most talked about stocks on r/WallStreetBets, as compiled by Swaggystocks.
NASDAQ:AACG
by AlenCiken
Why LAIX Stock Price Increased Over 100% in Pre-MarketWhy LAIX Stock Price Increased Over 100% in Pre-Market LAIX is an AI company that provides online English learning products and services in China. Since the company has not announced any news directly and there are no SEC reports to trigger a stock price increase, it appears there was a coordinated move on social media to drive the price up, similar to the reason why ATA Creativity Global went up more than 936% yesterday. I am seeing references to LAIX in stock trading groups on Facebook, Discord chat rooms, stock trading subreddits, Twitter hashtags, and YouTube channels before the market open. Many of these posts mentioned the advantages of the high volume and relatively low float of the stock. I noticed a user on StockTwits point out that the short percentage yesterday was 85% and there were no available shares to short on WeBull. “If you’re short on this ticker may I suggest you cover now before it gets out of control,” warned the user. Since the business model appears to be similar to ATA Creativity Global, it also appears that there is a sympathy play in effect as well. And since the company shares have a relatively small float and there is a high squeeze probability, day traders are also jumping on LAIX. pulse2.com
L
by AlenCiken
REE Automotive to List on NASDAQ Through Merger with $VCVCREE Automotive to List on NASDAQ Through Merger with 10X Capital Venture Acquisition Corp REE’s fully-flat and modular EV platforms are based on proprietary REEcorner technology, positioned to become the cornerstone of next-generation e-Mobility. The transaction is expected to provide more than $500 million of gross proceeds to the Company. This includes funds from a fully committed $300 million PIPE with participation from long-term strategic investors including Koch Strategic Platforms, Mahindra & Mahindra and Magna International. As a result of outsized demand, the PIPE offering was meaningfully oversubscribed and upsized. Pro forma equity value of the merger is approximately $3.6 billion and pro forma enterprise value of $3.1 billion, at the $10.00 per share PIPE price and assuming minimal 10X SPAC shareholder redemptions. targeting a $700 billion total addressable market REE has an orderbook comprised of signed indications of interest for over 250,000 platforms, representing 27% of their total cumulative expected revenue of $19.1 billion by 2026. The transaction will accelerate mass production of REEcorner technology and modular EV platforms, expected to begin in 2023. The proposed transaction expected to be completed by the end of the first half of 2021. www.businesswire.com
V
by AlenCiken
2
“Strong Buy” Penny Stock With Over 200% Upside on the Horizon“Strong Buy” Penny Stock With Over 200% Upside on the Horizon a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNS’s flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a ‘Durable Complete Response,’ defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the company’s asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brookline’s 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032,” Raja opined. “CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021… In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity,” the analyst added. finance.yahoo.com
NASDAQ:CNSP
by AlenCiken
2